271 related articles for article (PubMed ID: 38139060)
21. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
[TBL] [Abstract][Full Text] [Related]
22. Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.
Motais B; Charvátová S; Walek Z; Hrdinka M; Smolarczyk R; Cichoń T; Czapla J; Giebel S; Šimíček M; Jelínek T; Ševčíková T; Sobotka J; Kořístek Z; Hájek R; Bagó JR
Cells; 2021 Apr; 10(5):. PubMed ID: 33919155
[TBL] [Abstract][Full Text] [Related]
23. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
[TBL] [Abstract][Full Text] [Related]
24. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
25. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
[TBL] [Abstract][Full Text] [Related]
26. [Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma].
Tang WJ; Li Y; Zheng YH; Zhang L; Niu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):290-297. PubMed ID: 37157078
[TBL] [Abstract][Full Text] [Related]
27. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
[TBL] [Abstract][Full Text] [Related]
28. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
[TBL] [Abstract][Full Text] [Related]
30. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
Sun H; Martin TG; Marra J; Kong D; Keats J; Macé S; Chiron M; Wolf JL; Venstrom JM; Rajalingam R
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272304
[TBL] [Abstract][Full Text] [Related]
31. CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
Hejazi M; Zhang C; Bennstein SB; Balz V; Reusing SB; Quadflieg M; Hoerster K; Heinrichs S; Hanenberg H; Oberbeck S; Nitsche M; Cramer S; Pfeifer R; Oberoi P; Rühl H; Oldenburg J; Brossart P; Horn PA; Babor F; Wels WS; Fischer JC; Möker N; Uhrberg M
Front Immunol; 2021; 12():798087. PubMed ID: 35058934
[TBL] [Abstract][Full Text] [Related]
32. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
35. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P; Adeniji OS; Bordoloi D; Kinslow J; Martinson J; Parent DM; Hong KY; Koshy J; Kulkarni AJ; Zilberstein NF; Balk RA; Moy JN; Giron LB; Tracy RP; Keshavarzian A; Muthumani K; Landay A; Weiner DB; Abdel-Mohsen M
mBio; 2023 Feb; 14(1):e0339322. PubMed ID: 36728420
[TBL] [Abstract][Full Text] [Related]
36. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
Hambach J; Mann AM; Bannas P; Koch-Nolte F
Front Immunol; 2022; 13():1005800. PubMed ID: 36405759
[TBL] [Abstract][Full Text] [Related]
37. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
38. CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.
Stikvoort A; van der Schans J; Sarkar S; Poels R; Ruiter R; Naik J; Yuan H; de Bruijn JD; van de Donk NWCJ; Zweegman S; Themeli M; Groen R; O'Dwyer M; Mutis T
Hemasphere; 2021 Jul; 5(7):e596. PubMed ID: 34131635
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
40. NK cell therapy in relapsed refractory multiple myeloma.
Roshandel E; Ghaffari-Nazari H; Mohammadian M; Salimi M; Abroun S; Mirfakhraie R; Hajifathali A
Clin Immunol; 2023 Jan; 246():109168. PubMed ID: 36415020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]